Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Pharma
Roche touts near-complete MS suppression for injectable Ocrevus
Roche's subcutaneous Ocrevus helped 97% of multiple sclerosis patients achieve no relapse up to 48 weeks of treatment.
Angus Liu
Apr 17, 2024 11:00am
Novartis touts trial win, nabs priority review for Fabhalta
Apr 15, 2024 4:22pm
Top 20 pharma companies by 2023 revenue
Apr 15, 2024 3:00am
Novartis halts recruitment of trials for cancer drug Kisqali
Apr 10, 2024 11:09am
Amid restructuring, Novartis plots layoffs in development group
Apr 9, 2024 3:22pm
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
Apr 5, 2024 8:25am